Lumos Diagnostics Holdings Ltd (LDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lumos Diagnostics Holdings Ltd (LDX) has a cash flow conversion efficiency ratio of -0.490x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-3.02 Million) by net assets (AU$6.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lumos Diagnostics Holdings Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Lumos Diagnostics Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lumos Diagnostics Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lumos Diagnostics Holdings Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jeld-Wen Holding Inc
NYSE:JELD
|
0.098x |
|
Martin Midstream Partners LP
NASDAQ:MMLP
|
0.015x |
|
Bioxyne Ltd
AU:BXN
|
-0.064x |
|
Majestic Gold Corp.
V:MJS
|
0.030x |
|
Netanel Menivim Ltd.
TA:NTNB
|
N/A |
|
Bulten AB
ST:BULTEN
|
0.027x |
|
TOPMATERIAL LTD
KQ:360070
|
0.011x |
|
Turbogen Chp
TA:TURB
|
0.451x |
Annual Cash Flow Conversion Efficiency for Lumos Diagnostics Holdings Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Lumos Diagnostics Holdings Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$6.16 Million | AU$-9.33 Million | -1.516x | -1239.24% |
| 2023-12-31 | AU$7.11 Million | AU$946.00K | 0.133x | +113.11% |
| 2022-12-31 | AU$9.50 Million | AU$-9.64 Million | -1.015x | -0.62% |
| 2021-12-31 | AU$17.89 Million | AU$-18.04 Million | -1.008x | -439.75% |
| 2020-12-31 | AU$58.28 Million | AU$-10.89 Million | -0.187x | -10.16% |
| 2019-12-31 | AU$22.16 Million | AU$-3.76 Million | -0.170x | +34.83% |
| 2018-12-31 | AU$11.66 Million | AU$-3.03 Million | -0.260x | -168.72% |
| 2017-12-31 | AU$2.98 Million | AU$-288.67K | -0.097x | -- |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more